Related by context. All words. (Click for frequent words.) 74 pharmacological therapies 73 pharmacological treatments 72 pharmacologic treatments 70 pharmacological interventions 70 pharmacologic approaches 68 pharmacotherapies 67 dietary interventions 67 pharmacological intervention 67 psychotherapies 66 nonpharmacologic 66 antiplatelet therapies 66 comorbid depression 66 immunosuppressive therapies 66 lipid lowering agents 65 antiepileptics 65 CYT# potent vascular disrupting 65 therapeutic regimens 65 CAM modalities 65 pharmacologic 65 pharmacologic therapies 65 pharmacodynamic parameters 64 GnRH agonists 64 psychotherapeutic interventions 64 immunosuppressive regimens 64 neuropsychiatric diseases 64 anti angiogenic agents 64 somatostatin analogs 64 antiplatelet medications 64 aromatase inhibitors AIs 64 LHRH antagonists 64 inhaled bronchodilators 63 fibrate drugs 63 immunosuppressive agents 63 nondrug treatments 63 oral NSAIDs 63 CYP#A# inhibitors 63 thromboembolic disease 63 antiangiogenic agents 63 anticholinergic agents 63 antioxidant supplementation 63 adjuvant therapies 63 primidone 63 biphosphonates 63 cognitive behavioral therapies 63 direct thrombin inhibitors 63 chemopreventive agents 63 hypochondriasis 63 mu opioid agonists 63 antiplatelet drugs 63 newer atypical antipsychotics 63 pharmacologic interventions 63 mixed hyperlipidemia 63 receptor subtypes 63 pharmacological therapy 63 pharmacologic intervention 63 Relaxation techniques 63 HIF PH inhibitors 63 pathophysiological mechanisms 62 neuroleptics 62 treating neuropathic pain 62 topical formulations 62 nonpharmacological 62 therapies 62 probiotic supplementation 62 atypical antipsychotic medications 62 etiologic factors 62 Glucocorticoids 62 CB1 antagonists 62 calcineurin inhibitors 62 anti angiogenic drugs 62 neoplastic diseases 62 neurobiological mechanisms 62 immunological mechanisms 62 therapeutic modalities 62 metabolic parameters 62 immunotherapeutic approaches 62 overactive bladder symptoms 62 atypical neuroleptics 62 anti androgens 62 anticonvulsant medications 62 PPAR gamma agonists 62 gabapentin Neurontin 62 prognostic markers 62 protein tyrosine phosphatases 62 immunomodulation 62 corticosteroid therapy 62 MMP inhibitors 62 HMG CoA reductase inhibitors 62 inhaled glucocorticoids 62 pain syndromes 62 Atypical antipsychotics 62 long acting bronchodilator 62 colorectal carcinogenesis 61 anticoagulant warfarin 61 mu opioid agonist analgesics 61 antidepressants SSRIs 61 hypoxic tumors 61 pharmacological 61 psychopharmacological 61 kidney urologic 61 hormonal therapies 61 myeloproliferative diseases 61 RISPERDAL ® 61 APTIVUS ritonavir 61 pathogenic mechanisms 61 trastuzumab Herceptin ® 61 NovaBay Aganocide compounds 61 pharmacotherapeutic 61 dyslipidemias 61 predictive biomarkers 61 anticonvulsants 61 biopsychosocial 61 NMDA antagonists 61 NUCYNTA R 61 Squalamine 61 noncancer pain 61 TLR antagonists 61 Cognitive behavioral 61 anticholinergic effects 61 MEK inhibitors 61 INVEGA ® 61 neurotrophic 61 small molecule activators 61 Corticosteroids 61 acamprosate 61 neurocognitive function 61 pyridostigmine 61 neuroleptic drugs 61 molecular biomarkers 61 lipid abnormalities 61 non pharmacological interventions 61 agomelatine 61 comorbid psychiatric disorders 61 comorbid disorders 61 mTOR inhibitors 61 lysosomal storage diseases 61 fluoxetine Prozac 61 topical NSAIDs 61 pathophysiologic 61 prostanoid 61 opiate analgesics 61 vasodilators 61 lipid parameters 61 cMET 61 vasomotor symptoms 61 lipid lowering therapies 61 psychosocial variables 61 HuLuc# 61 glial tumors 61 squalamine 61 comorbid psychiatric 60 non selective NSAIDs 60 constipation OIC 60 LNP formulations 60 Smac mimetics 60 antidiabetic medications 60 prophylactic anticoagulation 60 Inhaled corticosteroids 60 aldosterone antagonist 60 riociguat 60 diabetic kidney 60 CYP#D# inhibitors 60 neuroprotective agent 60 tumor subtypes 60 antithrombotic therapy 60 antiandrogens 60 somatic symptoms 60 dyslipidaemia 60 monoamine oxidase inhibitors 60 ergot alkaloids 60 ursodeoxycholic acid 60 leukotriene receptor antagonists 60 tiagabine 60 serotonin reuptake inhibitors 60 nonpharmacological treatments 60 KL4 surfactant 60 Anticonvulsant 60 aetiology 60 neuroleptic 60 biologic DMARDs 60 pharmacogenetic testing 60 radiolabeled TM# 60 neuropsychiatric symptoms 60 Aggrastat ® tirofiban hydrochloride 60 antidepressant efficacy 60 antiemetics 60 nutrient supplementation 60 pleiotropic effects 60 imatinib resistance 60 myelofibrosis polycythemia vera 60 H2 receptor antagonists 60 molecularly targeted therapies 60 pharmacological chaperone 60 Herbal medicines 60 hematopoietic malignancies 60 primary hyperparathyroidism 60 prognostic biomarkers 60 validating biomarkers 60 neurocognitive deficits 60 underlying pathophysiology 60 paroxetine Paxil 60 antiepileptic drugs AEDs 60 JAK inhibitors 60 biologic pathways 60 EGFR inhibitors 60 SERMs 60 tamoxifen Nolvadex ® 60 lenalidomide dexamethasone 60 Thiazolidinediones 60 intensive lipid lowering 60 pathophysiologic mechanisms 60 hormonal deficiencies 60 iron chelators 60 antiangiogenic drugs 60 seminomas 60 analgesic medications 60 anticancer treatments 60 Perforomist ™ Inhalation Solution 60 IgG1 antibodies 60 AChE inhibitors 60 endocrine therapies 60 thrombo embolic 60 interventional therapies 60 etiologic 60 ganaxolone 60 bone metabolism 60 Transcranial Magnetic Stimulation TMS 60 act synergistically 60 thrombolytic agents 60 TNF alpha antagonist 60 thrombogenic 60 alcoholic fatty liver 60 SGLT2 inhibitors 60 exploratory endpoints 60 Cardiotoxicity 60 multitargeted 60 breast endometrial 60 AZILECT ® 60 analgesic effects 60 hepatotoxic 60 tricyclic antidepressants 60 neurocognitive impairment 60 inotropic agents 59 Androgen 59 behavioral interventions 59 psychostimulants 59 selective modulator 59 inhibits platelet aggregation 59 SIRT1 activators 59 primary dysmenorrhoea 59 psychiatric comorbidity 59 neovascular diseases 59 poststroke depression 59 vidofludimus 59 Opioids 59 pharmacokinetic interactions 59 antidepressive 59 ocular disorders 59 sulphonylureas 59 psychopharmacologic 59 glitazones 59 antiarrhythmic medications 59 microtubule targeting 59 comorbid conditions 59 venlafaxine Effexor 59 hematological disorders 59 H2 antagonists 59 EEG abnormalities 59 oral anticoagulants 59 neurobiological underpinnings 59 GVAX Pancreas Vaccine 59 topical calcineurin inhibitors 59 systemic fungal infections 59 secondary amenorrhea 59 HCV protease inhibitors 59 inotropes 59 somatoform disorders 59 investigational therapies 59 antidiabetic drugs 59 maladaptive behaviors 59 dopaminergic therapy 59 paricalcitol 59 pulmonary hypertension PH 59 adjunctively 59 aripiprazole Abilify 59 p# activation 59 Anthracycline 59 drugs NSAIDS 59 myeloproliferative disorders 59 compensatory mechanisms 59 phosphodiesterase inhibitors 59 allogeneic HSCT 59 metaanalysis 59 aspirin clopidogrel 59 leukotriene receptor antagonist 59 β blockers 59 etiologies 59 clevidipine 59 rheumatoid arthritis osteoarthritis ankylosing 59 phenelzine 59 subgroup analyzes 59 pramlintide metreleptin combination 59 therapeutic interventions 59 inhibitory neurotransmitters 59 integrative approaches 59 resolvins 59 Umbilical cord stem cells 59 vascular endothelial dysfunction 59 multiple sclerosis rheumatoid arthritis 59 degenerative neurological diseases 59 thyrotropin 59 immune modulating 59 dietary modification 59 NMDA antagonist 59 statin medications 59 chronic periodontitis 59 Cognitive Behavioral Therapy 59 DMARDS 59 immunological diseases 59 Warfarin Coumadin 59 dietary antioxidants 59 interferon IFN 59 flecainide 59 postoperative AF 59 desmopressin 59 infliximab Remicade 59 benign prostatic hypertrophy BPH 59 neurogenic 59 opiod 59 MAO inhibitors 59 neurologic disorders 59 immunotoxins 59 rheumatological 59 enzastaurin 59 Pharmacologic 59 STAT3 signaling 59 COX inhibitors 59 Meta analyzes 59 steroid inhalers 59 GI motility disorders 59 Bisphosphonate 59 cardiometabolic disorders 59 Subtypes 59 APTIVUS 59 chemoprevention trials 59 Adverse effects 59 non ulcer dyspepsia 59 Ischemic 59 Heavy snorers 59 chronic opioid 59 myoclonus 59 mitochondrial toxicity 59 osteopathic manipulation 59 oxcarbazepine 59 antiangiogenic 59 adrenal function 59 somatic complaints 59 Generalized Anxiety Disorder 59 antiarrhythmic 59 lymphoma subtypes 59 hawthorn extract 59 coinfected patients 59 antidiabetic medication 59 nociceptive pain 59 growth hormone secretion 59 antiangiogenic therapy 59 thoracoscopic lobectomy 59 mitochondrial disorders 59 anticholinergic medications 59 PPARγ 59 Homeopathic medicines 59 rufinamide 59 oral anticoagulation 59 molecular mechanisms underlying 59 electrophysiologic 59 anti epileptics 59 Thyroid disorders 59 anticancer therapies 59 Lipoic acid 59 diabetic gastroparesis 59 prostacyclins 59 multimodality therapy 59 stratifying patients 59 Herbal remedies 59 haematological malignancies 59 rheumatic disorders 59 SIADH 59 urothelial cancer 59 typical antipsychotics 59 gynecologic procedures 58 Mellaril 58 SPRIX ® 58 Calorie restriction 58 perfusion abnormalities 58 p# inhibitors 58 extramedullary 58 EGFR tyrosine kinase inhibitors 58 lipid lowering medications 58 neuroinflammatory 58 pathophysiological processes 58 immunosuppressive regimen 58 noscapine 58 dopamine antagonists 58 MGd 58 opioid analgesia 58 myopathy rhabdomyolysis 58 anticonvulsant medication 58 ibudilast 58 T1DM 58 bioinformatic approaches 58 antifungal medications 58 skeletal metastases 58 antihypertensive therapy 58 NSAIDs aspirin 58 risperidone Risperdal 58 tardive dyskinesia TD 58 intestinal motility 58 tricyclic antidepressant 58 tricyclics 58 PXD# 58 secondary hyperparathyroidism 58 TLR9 agonists 58 antihypertensive agents 58 Dopamine agonists 58 metabolic abnormalities 58 cediranib 58 pharmacogenetic tests 58 endophenotypes 58 cognitive impairment associated 58 esophagogastric 58 signaling cascades 58 BEXXAR Therapeutic Regimen 58 Genetic variants 58 intravenous bisphosphonates 58 menopausal symptom 58 mu opioid 58 anticancer therapy 58 hereditary predisposition 58 enzyme inhibitors 58 HAART regimens 58 stimulant medications 58 hemoglobinopathies 58 aldosterone antagonists 58 diagnostic modality 58 developmental neurotoxicity 58 postmenopausal hormone replacement 58 C1 INH deficiency 58 curative therapies 58 chemosensitivity 58 EGFR antibodies 58 chronic thromboembolic pulmonary 58 etiological 58 postmenopausal hormone 58 APTIVUS r 58 systemic immunosuppressive drugs 58 KRAS status 58 Th2 cytokines 58 Surgical resection 58 mGluR2 NAM 58 cardioprotection 58 Thal Dex 58 psychoeducation 58 VDAs 58 Nonsteroidal anti inflammatory 58 amisulpride 58 Prostacyclin 58 rBChE 58 quetiapine Seroquel 58 antisense oligonucleotides 58 serotonin reuptake inhibitors SSRIs 58 antithrombotic agents 58 Mitoxantrone 58 Fibrates 58 Estrogen Receptor 58 opiate dependence 58 Hormonal therapy 58 Mindfulness Based Cognitive Therapy 58 homoeopathic remedies 58 fibrotic disease 58 neuro psychiatric disorders 58 immunomodulatory effects 58 neurotrophic factors 58 apoptotic pathway 58 Pharmacological 58 thalidomide Thalomid 58 causal pathways 58 periprocedural MI 58 Psychosocial interventions 58 stem cell transplantations 58 antiinflammatory drugs 58 Genetic predisposition 58 pharmacologic therapy 58 memantine Namenda 58 standard chemotherapy regimens 58 adult neurogenesis 58 COMT inhibitors 58 efalizumab 58 tolerability profiles 58 myelomas 58 Micro RNAs 58 Virulizin ® 58 L lysine 58 immunodeficiency disorders 58 antiarrhythmic drugs 58 Symadex 58 STEP BD 58 molecular abnormalities 58 nongenetic 58 Cardiopulmonary bypass 58 prophylactic therapy 58 electro acupuncture 58 erlotinib Tarceva 58 chemopreventive agent 58 small molecule thrombopoietin 58 thetreatment 58 PDE4 inhibitors 58 arterial calcification 58 androgen deprivation 58 psychotherapeutic treatments 58 cardiotoxic 58 insulin sensitizers 58 EXJADE 58 renal fibrosis 58 synthetic retinoid 58 morbidities 58 tumor hypoxia 58 beta interferons 58 effector function 58 metastatic lymph nodes 58 selective inhibition 58 opioid analgesics 58 biomarker identification 58 genetic polymorphisms 58 mTOR inhibition 58 proliferative diabetic retinopathy 58 recurrent glioblastoma multiforme 58 nabilone 58 torsade de pointes 58 statins cholesterol lowering 58 immunostimulatory effects 58 multiple sclerosis inflammatory bowel 58 Erythropoietic therapies may 58 antiplatelets 58 LDL cholesterol lowering 58 stimulate neurogenesis 58 Calcitonin 58 DHEA supplementation 58 Granulocyte Colony Stimulating Factor 58 IFN beta 58 H. pylori eradication 58 shorter telomere length 58 dosing algorithm 58 Chronic pancreatitis 58 depressive illnesses 58 Tasimelteon 58 prenatal exposures 58 potentially modifiable 58 androgen deficiency 58 RAS blockers 58 antiplatelet agents 58 underlying molecular mechanisms 58 unmeasured factors 58 Cognitive behavioral therapy 58 Enbrel Humira 58 cardioprotective effects 58 lupus scleroderma 58 antithrombotic therapies 58 Comorbid 58 adjunctive therapies 58 omeprazole Prilosec 58 citalopram Celexa 58 Cytotoxic 57 varenicline Chantix 57 cellular pathways 57 meta cognitive 57 hypothalamic pituitary adrenal axis 57 anemias 57 #beta HSD1 57 biobehavioral 57 muscular dystrophies 57 mGluR2 57 antithrombotic 57 CLBP 57 inhaled anesthetics 57 radionuclide therapy 57 opioid induced 57 Carbamazepine 57 eprotirome 57 pharmacologic agents 57 monoamines 57 rheumatoid arthritis multiple sclerosis 57 AGILECT R 57 Subgroup analyzes 57 testosterone supplementation 57 haloperidol Haldol 57 pentoxifylline 57 metabolic disturbances 57 PDE# inhibitors 57 injectable formulations 57 VEGF inhibitors 57 renoprotective 57 tumor subtype 57 neurosensory 57 mda 7 57 dosing frequency 57 immuno modulatory 57 guideline concordant 57 K ras mutations 57 Comorbidities 57 tamoxifen raloxifene 57 neuroprotection 57 Dose adjustments 57 LHRH agonists 57 haematologic 57 Androgens 57 DNA methylation patterns 57 epilepsy Parkinson disease 57 cystic fibrosis chronic pancreatitis 57 erythropoietic 57 antisense inhibitors 57 physiologic mechanisms 57 LYSTEDA 57 insulin sensitizing drug 57 skin sparing mastectomy 57 FGFs 57 DNA methylation markers 57 therapeutic modality 57 tetrahydrobiopterin 57 motor neuron degeneration 57 CB2 receptor 57 Tectin TM 57 empiric therapy 57 fusion enhancers 57 TMS Therapy 57 Selective serotonin reuptake inhibitors 57 atherogenesis 57 thromboprophylaxis 57 arterial thrombosis 57 Muscle relaxants 57 Degarelix 57 neuropsychological assessment 57 glatiramer acetate 57 antipsychotic induced 57 LLLT 57 rheumatologic 57 Spinal manipulation 57 acute respiratory tract infections 57 nonalcoholic steatohepatitis NASH 57 opioid antagonists 57 gemifloxacin 57 paliperidone 57 adjunct therapy 57 ocular inflammatory 57 visilizumab 57 antiarrhythmic drug 57 androgen depletion therapy 57 FSAD 57 neuroprotective therapies 57 macrovascular disease 57 platelet activation 57 antiangiogenic agent 57 interpersonal psychotherapy 57 teratogens 57 Chronic Heart Failure 57 LRP5 57 glycoprotein IIb IIIa inhibitors 57 rheumatic diseases 57 neurogenerative diseases 57 inhaled budesonide 57 anticonvulsant drugs 57 G6PD deficiency 57 Cognitive impairment 57 organophosphorus compounds 57 mycophenolate mofetil 57 TPMT 57 alpha interferons 57 Methotrexate MTX 57 thiazide 57 antitumor efficacy 57 Severe Primary IGFD 57 histologies 57 SARMs 57 paroxetine sertraline 57 endometriosis ovarian cysts 57 somatostatin analogues 57 endothelin antagonists 57 plasminogen activators 57 acetylcholinesterase inhibitors 57 physico chemical properties 57 symptomatic hyponatremia 57 mechanistic insights 57 epilepsies 57 untreated celiac disease 57 biologic plausibility 57 TLR agonists 57 anticholinergic drugs 57 NUCYNTA ™ 57 LOVENOX R 57 agonists antagonists 57 Salmeterol 57 Topical treatments 57 convulsive disorders 57 psychobiological 57 Preclinical studies suggest 57 Aviptadil 57 intranasal corticosteroids 57 ziconotide 57 MAGE A3 ASCI 57 Parkinson disease Alzheimer disease 57 systemic corticosteroid 57 androgen depletion 57 Topiramate 57 lupus multiple sclerosis 57 commonly prescribed antidepressants 57 Entereg R 57 Inhaled nitric oxide 57 mutated K ras 57 breast cancer subtypes 57 degenerative disorders 57 ABCB1 57 genetic determinants 57 postmenopausal estrogen 57 Angiotensin converting enzyme 57 potassium sparing diuretics 57 aerosolized KL4 surfactant 57 gefitinib Iressa 57 affective disorders 57 immunomodulatory agents 57 adrenal suppression 57 nonalcoholic steatohepatitis 57 pharmacotherapy 57 Th2 responses 57 peptidic 57 neuroimaging studies 57 chronic myocardial ischemia 57 dysrhythmias 57 deacetylase inhibitors 57 synthetic progestin 57 bevacizumab Avastin Genentech 57 CAM therapies 57 uric acid lowering 57 pharmacodynamic endpoints 57 chemotherapeutic agents 57 nocturnal enuresis 57 alexithymia 57 Anti psychotics 57 Cognitive Behavioral Therapy CBT 57 levodopa induced 57 psychoactive medications 57 melatonin supplements 57 Triptans 57 tumor necrosis 57 osteoarthritis rheumatoid arthritis 57 euthymic patients 57 neuropsychological impairments 57 pimozide 57 histone deacetylase HDAC inhibitors 57 doxorubicin HCl 57 Antidepressant medications 57 neuropathic pain nerve 57 Antioxidant supplements 57 brain penetrant 57 Alequel 57 androgen hormones 57 LPM TM 57 prognostic indicators 57 adjuvant systemic 57 recombinant erythropoietin 57 serum biomarkers 57 cytotoxic agents 57 proteasome inhibitors 57 neurobiological basis 57 Non Steroidal Anti Inflammatory 57 postoperative morbidity 57 HyQ 57 p# inhibitor 57 microtubule inhibitor 57 glucocorticoid receptors 57 histone deacetylase inhibitor 57 CEACAM1 57 IVIG therapy 57 coronary revascularization procedures 57 HDAC inhibition 57 sotalol 57 juvenile idiopathic arthritis 57 Valproic acid 57 INVEGA ™ 57 differential gene expression 57 pouchitis 57 familial predisposition 57 constipation predominant IBS 57 LHRH analogues 57 potent inhibitors 57 antidiabetic therapy 57 Adjunctive 57 carotid atherosclerosis 57 Tr DNA 57 thyrotropin levels 57 Exelixis compounds 57 postoperative radiotherapy 57 phosphate binders 57 MGN# 57 induced anemia 57 aromatase inhibitor therapy 57 Phe restricted diet 57 bile acid metabolism 57 antithrombotics 57 TRAIL receptor antibodies 57 Adjuvant therapy 57 inhaled corticosteroid therapy 57 Retinoic Acid 57 insulin sensitizing 57 postoperative atrial fibrillation 57 MBCT 57 d l leucovorin 57 TTR amyloidosis 57 Interpersonal psychotherapy 57 atherosclerotic renal artery stenosis 57 Inflammatory diseases 57 fermentable carbohydrates 57 partial agonists 57 overlapping toxicities 57 Aromatase inhibitors 57 hippocampal neurogenesis 57 plasma lipid 57 calcium antagonists 57 SIRT1 activation 57 IGF IR 57 mecamylamine 57 inactivated influenza vaccines 57 Alzheimer disease vascular dementia 57 #HT#A 57 factor TNF 57 cranial irradiation 57 NMES 57 KAPVAY ™ 57 R#/MEM 57 neurosteroid 57 biochemical abnormalities 57 cystinosis patients 57 CTAP# Capsules 57 psychopathologies 57 IDH mutations 56 antipsychotic medications 56 CTLA4 Ig 56 reuptake inhibitor 56 thrombotic complications 56 oral prodrug 56 blood clot dissolver 56 venous thromboembolism VTE prophylaxis 56 environmental toxicants 56 intracellular pathways 56 cerebral perfusion 56 cholinesterase inhibitors 56 LibiGel ® 56 imexon 56 antitumour 56 mycosis fungoides 56 opioid bowel dysfunction 56 epidural steroid injections 56 diagnostic molecular imaging 56 salicylates 56 teratogenic 56 psychiatric comorbidities 56 caspofungin 56 conjugated estrogen 56 WARNINGS Myopathy Rhabdomyolysis 56 MAOIs 56 PI3K Akt 56 #ME# 56 heparins 56 hypervascular tumors 56 endothelin antagonist 56 Androgen deprivation therapy 56 calcineurin inhibitor 56 Detrol Detrol LA 56 rxRNA ™ compounds 56 biologic therapeutics 56 endoxifen 56 warfarin therapy 56 SCIg 56 metabonomics 56 CYP #A# 56 pituitary adenomas 56 proton MR spectroscopy 56 APOE genotype 56 novel radiopharmaceuticals 56 topical corticosteroids 56 amyloid plaque formation 56 HbF 56 multicenter trials 56 immune modulators 56 idraparinux 56 Soy isoflavones 56 intracranial stenosis 56 targeting PCSK9 56 cardiac perfusion imaging 56 psoriasis Crohn disease 56 NSAID induced 56 adipiplon 56 Decitabine 56 metabolic syndromes 56 CCX# 56 rxRNA TM compounds 56 CellCept mycophenolate mofetil 56 HER2 overexpression 56 intermittent hypoxia 56 immunoregulation 56 sertraline Zoloft 56 maximally tolerated lipid lowering 56 proliferative disorders 56 kallikrein 56 Dupuytren Disease 56 PDE7 inhibitors 56 neuro stimulation 56 therapeutic armamentarium 56 noninfectious uveitis 56 convergent validity 56 oncologic outcomes 56 rheumatoid arthritis inflammatory bowel 56 Epidermal Growth Factor Receptor 56 trospium 56 biopsychosocial model 56 nonsteroidal 56 generalisability 56 oral hypoglycemic agent 56 lesional 56 protein misfolding diseases 56 gastro intestinal inflammation 56 conventional antipsychotics 56 glucagon receptor 56 novel VDA molecule 56 folate metabolism 56 genetic loci 56 epithelial tumors 56 Vidofludimus 56 agonist antagonist 56 Alpha lipoic acid 56 kinase inhibition 56 fulvestrant 56 epigenetic therapies 56 inhibiting COX 56 murine models 56 bacterial prostatitis 56 ß blockers 56 hormonally responsive 56 benfotiamine 56 anti amnesic 56 pharmacodynamic PD 56 SUSTENNA TM 56 topical retinoids 56 serous ovarian cancer 56 Guaifenesin 56 Combination therapy 56 metformin sulfonylurea 56 renal toxicity 56 Alzheimer disease cognitive impairment 56 antimetabolites 56 transdermal gel 56 demyelinating diseases 56 eicosanoids 56 gene polymorphisms 56 ACV1 56 atherothrombotic 56 neutropenic patients 56 concomitant medications 56 ADAMTS# 56 VAPRISOL 56 lapatinib Tykerb 56 vitamin D analogs 56 Interferon Beta 56 hematological parameters 56 affective psychoses 56 Radiofrequency ablation 56 dosage regimens 56 oral anticoagulant therapy 56 neuroinflammatory diseases 56 velafermin 56 SSRI antidepressant 56 monogenic diseases 56 Starlix 56 p#INK#a 56 primary aldosteronism 56 nicotine nasal spray 56 asplenia 56 mGluR5 antagonist 56 Paliperidone 56 rxRNA compounds 56 unmeasured confounders 56 macrolide antibiotics 56 syndromal 56 Abciximab 56 Cerashield ™ 56 cetirizine Zyrtec 56 cardiac repolarization 56 nonmelanoma skin cancers 56 vivo potency 56 PHY# [002] 56 class mGluR5 inhibitor